[EN] COMPOSITIONS AND METHODS OF TREATMENT FOR SARS-COV-2 THROUGH PAPAIN PROTEASE INHIBITION [FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU SRAS-COV-2 PAR INHIBITION DE PROTÉASE À PAPAÏNE
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3
作者:Peter E. Cockram、Benjamin T. Walters、Aaron Lictao、Frances Shanahan、Ingrid E. Wertz、Scott A. Foster、Joachim Rudolph
DOI:10.1021/acschembio.3c00312
日期:2024.1.19
[EN] COMPOSITIONS AND METHODS OF TREATMENT FOR SARS-COV-2 THROUGH PAPAIN PROTEASE INHIBITION<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU SRAS-COV-2 PAR INHIBITION DE PROTÉASE À PAPAÏNE
申请人:UNIV GEORGIA
公开号:WO2022072975A1
公开(公告)日:2022-04-07
In one aspect, the disclosure relates to viral papain protease inhibitors, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating and/or preventing COVID-19 and other coronavirus diseases using the same. In one aspect, the papain protease inhibitors have a core or linker structure featuring at least one nitrogen atom and substituted or unsubstituted cycloalkyl, aromatic, or heteroaromatic groups on either side of the core structure. In another aspect the papain protease inhibitors are capable of ablating viral deubiquitination and/or deISGase activity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
papain-like protease (PLpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a critical role in the proteolytic processing of viral polyproteins and the dysregulation of the host immune response, providing a promising therapeutic target. Here, we report the structure-guide design of novel peptidomimetic inhibitorscovalently targeting SARS-CoV-2 PLpro. The resulting inhibitors demonstrate